Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. The incidence of pancreatic cancer in African Americans is 50% to 90% higher than the incidence in other racial groups. African Americans also have the worst prognosis. This is an evidence-based review of pancreatic cancer in African Americans with particular emphasis on baseline characteristics, treatment, and survival.
We queried PubMed in search for articles describing racial disparities in pancreatic cancer. Two categories of terms were “anded” together: pancreatic cancer terms and race terms. The last search was performed on November 14, 2013.
We summarized the data on pancreatic cancer baseline characteristics, treatment, and survival for African Americans that we obtained from the following databases: (1) Surveillance, Epidemiology, and End Results, 1988–2008; (2) California Cancer Registry 1988–1998; (3) Cancer Survivor Program of Orange County/San Diego Imperial Organization for Cancer Control, 1988–1998; and (4) Harris County, 1998–2010.
Overall, pancreatic cancer survival of African Americans has not significantly improved over the past several decades despite advances in multimodality therapy; African Americans continue to face worse outcomes than whites. Although baseline characteristics, treatment, and biological factors offer some explanation, they do not completely explain the disparities in incidence and survival.
From the *Michael E. DeBakey Department of Surgery, †The Elkins Pancreas Center, ‡Dan L. Duncan Cancer Center, and §Department of Medicine, Baylor College of Medicine, Houston, TX.
Received for publication March 26, 2014; accepted October 29, 2014.
Reprints: George Van Buren II, MD, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 6620 Main St, Suite 1350, Houston, TX 77030 (e-mail: George.email@example.com).
The authors declare no conflict of interest.